Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.
Krina K PatelJatin J ShahLei FengHans C LeeElisabet M ManasanchJasper OlsemAshley MorpheyXiao Jiao HuoSheeba K ThomasQaiser BashirMuzaffar H QazilbashDonna M WeberRobert Z OrlowskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The addition of ixazomib to lenalidomide maintenance demonstrated a better than expected PFS compared with historical data using lenalidomide alone and was safe and tolerable.